We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

By LabMedica International staff writers
Posted on 18 Aug 2014
Print article
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).
For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer.

Ovarian cancer causes more deaths than any other gynecologic cancer. It is the seventh most commonly diagnosed cancer in women worldwide, with an estimated 230,000 cases diagnosed around the world every year and there are approximately 150,000 deaths from the disease. In the European Union, there are an estimated 44,000 cases of ovarian cancer every year, and nearly 30,000 women will die from the disease.

The newly approved drug is bevacizumab, an antibody derived from Chinese hamster ovary cells combined with a mouse protein. It sold in the United States under the brand name Avastin and is manufactured by Genentech (San Francisco, CA, USA), a subsidiary of Roche (Basel, Switzerland).

Avastin works by blocking the action of vascular endothelial growth factor (VEGF). VEGF stimulates the growth of new blood vessels in the process known as angiogenesis. Avastin antibodies bind tightly to VEGF and inactivate it. As a result, new blood vessels are not formed, and cancer tumor growth is inhibited by lack of an adequate supply of blood. Treated tumors cannot get larger and may even shrink. Thus, Avastin does not work directly on the tumor, but prevents its growth by reducing its supply of blood.

The EC has now approved the use of Avastin in combination with the chemotherapeutic drugs paclitaxel, topotecan, or pegylated liposomal doxorubicin as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. Approval was based on results of the phase III AURELIA study, which involved women with recurrent, platinum-resistant ovarian cancer who received either chemotherapy or Avastin in combination with chemotherapy. Results showed that the addition of Avastin to chemotherapy gave a clinically meaningful benefit, nearly doubling the median progression free survival (PFS) from 3.4 months to 6.7 months.

“European approval of Avastin for recurrent, platinum-resistant ovarian cancer is good news because Avastin can help women live longer without their cancer progressing, which is an important treatment goal in advanced disease,” said Dr. Sandra Horning, chief medical officer and head of global product development at Roche. “Avastin is the first biologic medicine approved by the EU for women with this difficult to treat disease.”

Related Links:

Genentech
Roche


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.